What do systematic reviews say?

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 506 participants
  Moderate

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 0.26 [0.03, 2.43]
  1 study · 95 participants
  Very low

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

Homeopathic medicinal products (non‐individualised treatment) showed no clear difference in recurrence of ARTI compared with placebo or usual care (low certainty).

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  OR 0.6 [0.21, 1.72]
  3 studies · 735 participants
  Low

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Homeopathic medicinal products (non‐individualised treatment) vs placebo or usual care

The review found no eligible studies for this question.

• Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Individualised homeopathic medicine (two doses over 24 hours) vs placebo

Individualised homeopathic medicine (two doses over 24 hours) led to higher complete ulcer healing by end of study (day 6) compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 days
  RR 2.00 [1.39, 2.89]
  1 study · 100 participants
  GRADE not reported

Individualised homeopathic medicine (two doses over 24 hours) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 days
  A statistically significant difference was reported in mean pain score and mean ulcer size favouring the homeopathic group (P<0.05). Summary data not presented, precluding further analysis.
  1 study · 100 participants
  GRADE not reported

Individualised homeopathic medicine (two doses over 24 hours) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 days
  No participant needed to discontinue treatment due to adverse events.
  1 study · 100 participants
  GRADE not reported

Individualised homeopathic medicine (two doses over 24 hours) vs placebo

Individualised homeopathic medicine (two doses over 24 hours) led to higher pain free by end of study (day 6) compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 days
  RR 2.00 [1.39, 2.89]
  1 study · 100 participants
  GRADE not reported

Interventions directed at individuals: full financial coverage vs no financial coverage

Interventions directed at individuals: full financial coverage probably leads to higher abstinence from smoking compared with no financial coverage (moderate certainty).

• Healthcare financing systems for increasing the use of tobacco dependence treatment 2017 · Cochrane Headline outcomes only
  RR 1.77 [1.37, 2.28]
  6 studies · 9333 participants
  Moderate

Individualised oral care plan based on a multidisciplinary assessment vs usual care

• Oral hygiene interventions for people with intellectual disabilities 2019 · Cochrane All outcomes

  Medium term (6 weeks to 12 months)
  Individualised oral care plan vs usual care. Subjective Oral Hygiene Rating scale 1-5 and Improvement Differential, mean 12 months; SOHR 2.97 (intervention) vs 3.10 (control); improvement differential 38% vs 5%; 79…
  1 study · 79 participants
  Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  Moderate

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

An extended NVP plus ZDV dual regimen administered to infants for 14… showed no clear difference in HIV Transmission at 9 months among those whose HIV diagnostic… compared with an extended NVP regimen administered to infants (moderate certainty).

• Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
  HR 1.23 [0.83, 1.81]
  1 study · 2013 participants
  Moderate